Loading stock data…
ERAS
$13.33+0.46 (+3.57%)
Market OpenUpdated 3:56 PM EDT
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Erasca, Inc. in the Healthcare sector is trading at $13.33 with a market capitalization of $4.1B. Wall Street consensus targets $21.00 (10 analysts), implying a +57.5% move over the next 12 months. The stock is currently 45% below its 52-week high of $24.28, remaining 64.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +57.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$13.33
Potential Downside
0%
Whystock Fair Value$13.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$21.00+57.5%
Range$12.00 – $30.00
Fundamentals
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-70.39%
Volume
Today's trading volume
3.86M
Recent News
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents
Erasca recently faced a legal challenge from competitor Revolution Medicines over alleged trade secret misappropriation and patent infringement tied to its lead oncology candidate ERAS-0015, prompting a shareholder rights law firm to investigate whether investors were misled about the strength of its intellectual property position. This dispute strikes at the core of Erasca’s pan-RAS development story, as ERAS-0015 underpins both its pipeline focus and its emerging clinical and partnership...
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations
Erasca Inc. (NASDAQ:ERAS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Erasca Inc. (NASDAQ:ERAS) announced a supply agreement and a clinical trial partnership with Merck. The collaboration is aimed at facilitating the AURORAS-1 clinical proof-of-concept research. This research thoroughly assesses the exclusive pan-RAS molecular glue ERAS-0015 […]
Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says
Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its po
Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20
Erasca Inc. (NASDAQ:ERAS) is one of the best growth stocks under $20 to buy. On May 11, Erasca reported positive progress for its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for its lead candidate, ERAS-0015, in KRAS G12X lung and pancreatic cancers. The company is accelerating development, having already initiated monotherapy […]